Advice Pool - Finance

We know that a good fund manager plays important roles in fund's performance and success. When a fund manager leaves, does it affect fund performance? What happen to your investments

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

? So what does a change in fund managers mean to a unit trust fund investors? Should you worry when a fund manager leaves?

First of all, whether or not the absence of any one fund m

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

nager would greatly impact the fund's performance depends on how the company's investment management process is structured. Some companies assign only one man show (a star fund manage

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

r like Chief Investment Officer) to run and call the shots while others could have different members of the investment team focusing on different asset classes or on specific sectors i

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

stead of funds.

Therefore, where it is a team effort, the leave of an individual fund manager should not impact fund performance so much. However, when the investment head leaves, th

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

ere could be a difference in the funds' investment performance because the whole fund investment approach could be changed.

Besides the structure of the team and the person who is lea

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

ing, it is important to find out whether the company has set guidelines for the fund management process. Then no matter how good or bad the manager is, the process will largely determ

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

ine the performance. We can't deny that the fund managers play an important role in terms of risk appetite in picking up certain stocks but the most important thing is the whole inves

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

ment process. Fund managers will gather everything to assess certain risks and even if they're the designated fund manager, they get input from other members in the team.

If the inve

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

stment concept and system are in place, investors will not be too worried about a fund manager leaving. Within the fund management team, there is fund management expertise, experience

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

knowledge and adaptability. Especially when the team is big, other members can help with the fund managing in the interim.

However, it's arguable that fund management boils down to

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

he fund manager's decision making, because philosophy and approach aside, the fund managers still have a lot of discretion. The other party involved is the investment committee, but t

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

ypically it does not dictate investment decision making except making sure that proper due diligence is done before investing and that the parameters are adhered to.

In 2004, US fund

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

racking company MorningStar compared funds that experienced management changes with those that kept their managers in the last decade. The result, about half maintained their performa

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

nce, for better or worse. The top performing funds from 1993-2000 continued to outperform their benchmark indices regardless of management changes.

Thus, if you heard the fact that y

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

ur fund manager is leaving, should you stay in or move your money?

Firstly, don't panic! If the fund has been underperforming, a new manager may actually be good news. Evaluate whet

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

her it's just a normal turnover where a single fund manager resigns, or there's a complete change in management. A change in management could mean a total revamp of the entire operati

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

ns of the fund management company. The objectives and investment strategy could be totally different. It's important to determine if the policies are still within the investors' inve

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

stment objectives. If it differs, then you can opt to leave.

If you've decided to stay in, keep an eye on the fund's performance. Industry players say it takes about six months to a

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

year before you can tell whether the new fund manager can perform.

Last but not least, if you are a new investor and you have not made any return, it is probably not very wise to move

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.advicepool.org.ua/article/103032/advicepool-Fund-Manager-Leaves-The-Impact.html">Fund Manager Leaves: The Impact</a>

BB link (for phorums):
[url=http://www.advicepool.org.ua/article/103032/advicepool-Fund-Manager-Leaves-The-Impact.html]Fund Manager Leaves: The Impact[/url]

How can you use the internet to promote your business and make more money? Is there something you can do to make more money online? Find out here.

If you attend networking clubs, service clubs or Chamber of Commerce Meetings to meet people, promote your company and also help the local community while joining with other businesses in a common cause, well I salute you for your efforts.

Debt consolidation loan bad credit enables bad credit people to take loan for paying off all debts in one go at lower interest rate. The loan is equally available in its unsecured version also. The article discusses different key aspects of the loan.

Tags

Links

Advice Pool - Fund Manager Leaves: The Impact

Related Articles: